EW logo

EDWARDS LIFESCIENCES CORP

EWNYSE
πŸ† #269 by market capEarnings Nov 4 Β· PostUS Equity
$91.79β–² $0.99 (+1.09%)
Market closed Β· at close
πŸ””
Track EW
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.1%
7dβ–² 1.9%
14dβ–² 4.2%
30dβ–² 4.2%
ytdβ–² 7.7%
1yβ–² 11.0%
🏦Market Cap
$52.91B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
14.6%
Healthy
πŸ“ŠGross Margin
77.8%
High
πŸ’΅FCF Margin
22.3%
Strong
βš–οΈP/S Ratio
8.1x
Elevated
Otter Score
76
Strong

Trading Snapshot

Day Range
$90.25 – $92.03
52-Week Range
$74.66 – $96.29
Volume (shares)
115,874
Avg Volume (shares)
β€”
Shares Outstanding
576.4M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$6.07B
Last Q Revenue
$1.74B
P/E Ratio
52.5
P/S Ratio
8.1x
EPS (TTM)
$1.73
Dividend Yield
β€”
Dilution (1yr)
βˆ’1.5%
EW logo

EDWARDS LIFESCIENCES CORP

EW
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6.1Bβ–² +11.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
78.1%β–Ό βˆ’1.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$1.6Bβ–² +18.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.3Bβ–² +360.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
581.8Mβ–Ό βˆ’1.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2.2Bβ–Ό βˆ’$112M YoY
StockOtter Β· stockotter.space

About EDWARDS LIFESCIENCES CORP

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

News unavailable.